APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biosimilar

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Biosimilar Market Analysis and Forecast 2026-2032

22 December 2025195 pages

Choose your research edition.

Industry ResearchBiosimilar Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Biosimilar Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Biosimilar Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biosimilar Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Biosimilar Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Biosimilar market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Biosimilar is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Biosimilar is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Biosimilar is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Biosimilar is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Biosimilar include Qilu Pharmaceutical, Bio-Thera, Zhejiang Hisun, Shanghai Henlius, Innovent Biologics, Jiangsu Hengrui, Gan&Lee, Tonghua Dongbao and United Laboratory, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Biosimilar, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Biosimilar, also provides the revenue of main regions and countries. Of the upcoming market potential for Biosimilar, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biosimilar revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Biosimilar market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Biosimilar revenue, projected growth trends, production technology, application and end-user industry.

Biosimilar Segment by Company

Qilu Pharmaceutical

Bio-Thera

Zhejiang Hisun

Shanghai Henlius

Innovent Biologics

Jiangsu Hengrui

Gan&Lee

Tonghua Dongbao

United Laboratory

3SBIO

Luye Pharma

Biosimilar Segment by Type

Biosimilar Monoclonal Antibodies

Biosimilar Insulin

Others

Biosimilar Segment by Application

Cancer

Immunological Diseases

Diabetes

Others

Biosimilar Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Biosimilar in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Biosimilar company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biosimilar revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Biosimilar Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Biosimilar Monoclonal Antibodies Major Player Table 3. Biosimilar Insulin Major Player Table 4. Others Major Player Table 5. Global Biosimilar Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Cancer Major Player Table 7. Immunological Diseases Major Player Table 8. Diabetes Major Player Table 9. Others Major Player Table 10. Biosimilar Industry Trends Table 11. Biosimilar Industry Drivers Table 12. Biosimilar Industry Opportunities and Challenges Table 13. Biosimilar Industry Restraints Table 14. Global Biosimilar Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Biosimilar Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Biosimilar Market Share by Region (2021-2026) Table 17. Global Biosimilar Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Biosimilar Market Share by Region (2027-2032) Table 19. Global Biosimilar Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Biosimilar Revenue Market Share by Players (2021-2026) Table 21. Global Biosimilar Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Biosimilar Key Players Headquarters & Area Served Table 23. Global Biosimilar Players, Product Type & Application Table 24. Global Biosimilar Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Biosimilar by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Biosimilar Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Biosimilar Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Biosimilar Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Biosimilar Revenue Market Share by Type (2021-2026) Table 31. Global Biosimilar Revenue Market Share by Type (2027-2032) Table 32. Global Biosimilar Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Biosimilar Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Biosimilar Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Biosimilar Revenue Market Share by Application (2021-2026) Table 36. Global Biosimilar Revenue Market Share by Application (2027-2032) Table 37. Qilu Pharmaceutical Company Information Table 38. Qilu Pharmaceutical Business Overview Table 39. Qilu Pharmaceutical Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Qilu Pharmaceutical Biosimilar Product Portfolio Table 41. Qilu Pharmaceutical Recent Development Table 42. Bio-Thera Company Information Table 43. Bio-Thera Business Overview Table 44. Bio-Thera Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Bio-Thera Biosimilar Product Portfolio Table 46. Bio-Thera Recent Development Table 47. Zhejiang Hisun Company Information Table 48. Zhejiang Hisun Business Overview Table 49. Zhejiang Hisun Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Zhejiang Hisun Biosimilar Product Portfolio Table 51. Zhejiang Hisun Recent Development Table 52. Shanghai Henlius Company Information Table 53. Shanghai Henlius Business Overview Table 54. Shanghai Henlius Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Shanghai Henlius Biosimilar Product Portfolio Table 56. Shanghai Henlius Recent Development Table 57. Innovent Biologics Company Information Table 58. Innovent Biologics Business Overview Table 59. Innovent Biologics Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Innovent Biologics Biosimilar Product Portfolio Table 61. Innovent Biologics Recent Development Table 62. Jiangsu Hengrui Company Information Table 63. Jiangsu Hengrui Business Overview Table 64. Jiangsu Hengrui Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Jiangsu Hengrui Biosimilar Product Portfolio Table 66. Jiangsu Hengrui Recent Development Table 67. Gan&Lee Company Information Table 68. Gan&Lee Business Overview Table 69. Gan&Lee Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Gan&Lee Biosimilar Product Portfolio Table 71. Gan&Lee Recent Development Table 72. Tonghua Dongbao Company Information Table 73. Tonghua Dongbao Business Overview Table 74. Tonghua Dongbao Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Tonghua Dongbao Biosimilar Product Portfolio Table 76. Tonghua Dongbao Recent Development Table 77. United Laboratory Company Information Table 78. United Laboratory Business Overview Table 79. United Laboratory Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. United Laboratory Biosimilar Product Portfolio Table 81. United Laboratory Recent Development Table 82. 3SBIO Company Information Table 83. 3SBIO Business Overview Table 84. 3SBIO Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. 3SBIO Biosimilar Product Portfolio Table 86. 3SBIO Recent Development Table 87. Luye Pharma Company Information Table 88. Luye Pharma Business Overview Table 89. Luye Pharma Biosimilar Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Luye Pharma Biosimilar Product Portfolio Table 91. Luye Pharma Recent Development Table 92. North America Biosimilar Revenue by Type (2021-2026) & (US$ Million) Table 93. North America Biosimilar Revenue by Type (2027-2032) & (US$ Million) Table 94. North America Biosimilar Revenue by Application (2021-2026) & (US$ Million) Table 95. North America Biosimilar Revenue by Application (2027-2032) & (US$ Million) Table 96. North America Biosimilar Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. North America Biosimilar Revenue by Country (2021-2026) & (US$ Million) Table 98. North America Biosimilar Revenue by Country (US$ Million) & (2027-2032) Table 99. Europe Biosimilar Revenue by Type (2021-2026) & (US$ Million) Table 100. Europe Biosimilar Revenue by Type (2027-2032) & (US$ Million) Table 101. Europe Biosimilar Revenue by Application (2021-2026) & (US$ Million) Table 102. Europe Biosimilar Revenue by Application (2027-2032) & (US$ Million) Table 103. Europe Biosimilar Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. Europe Biosimilar Revenue by Country (2021-2026) & (US$ Million) Table 105. Europe Biosimilar Revenue by Country (US$ Million) & (2027-2032) Table 106. China Biosimilar Revenue by Type (2021-2026) & (US$ Million) Table 107. China Biosimilar Revenue by Type (2027-2032) & (US$ Million) Table 108. China Biosimilar Revenue by Application (2021-2026) & (US$ Million) Table 109. China Biosimilar Revenue by Application (2027-2032) & (US$ Million) Table 110. Asia Biosimilar Revenue by Type (2021-2026) & (US$ Million) Table 111. Asia Biosimilar Revenue by Type (2027-2032) & (US$ Million) Table 112. Asia Biosimilar Revenue by Application (2021-2026) & (US$ Million) Table 113. Asia Biosimilar Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia Biosimilar Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 115. Asia Biosimilar Revenue by Region (US$ Million) & (2021-2026) Table 116. Asia Biosimilar Revenue by Region (US$ Million) & (2027-2032) Table 117. SAMEA Biosimilar Revenue by Type (2021-2026) & (US$ Million) Table 118. SAMEA Biosimilar Revenue by Type (2027-2032) & (US$ Million) Table 119. SAMEA Biosimilar Revenue by Application (2021-2026) & (US$ Million) Table 120. SAMEA Biosimilar Revenue by Application (2027-2032) & (US$ Million) Table 121. SAMEA Biosimilar Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. SAMEA Biosimilar Revenue by Country (2021-2026) & (US$ Million) Table 123. SAMEA Biosimilar Revenue by Country (US$ Million) & (2027-2032) Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Biosimilar Image Figure 2. Global Biosimilar Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biosimilar Market Size Share 2021 VS 2025 VS 2032 Figure 4. Biosimilar Monoclonal Antibodies Image Figure 5. Biosimilar Insulin Image Figure 6. Others Image Figure 7. Global Biosimilar Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Biosimilar Market Size Share 2021 VS 2025 VS 2032 Figure 9. Cancer Image Figure 10. Immunological Diseases Image Figure 11. Diabetes Image Figure 12. Others Image Figure 13. Global Biosimilar Market Size (US$ Million) & (2021-2032) Figure 14. Global Biosimilar Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Biosimilar Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Biosimilar Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Biosimilar Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Biosimilar Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Biosimilar Revenue Market Share by Type (2021-2032) Figure 21. Global Biosimilar Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Biosimilar Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Biosimilar Revenue Market Share by Application (2021-2032) Figure 24. North America Biosimilar Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Biosimilar Revenue Share by Type (2021-2032) Figure 26. North America Biosimilar Revenue Share by Application (2021-2032) Figure 27. North America Biosimilar Revenue Share by Country (2021-2032) Figure 28. United States Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Biosimilar Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Biosimilar Revenue Share by Type (2021-2032) Figure 33. Europe Biosimilar Revenue Share by Application (2021-2032) Figure 34. Europe Biosimilar Revenue Share by Country (2021-2032) Figure 35. Germany Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Biosimilar Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Biosimilar Revenue Share by Type (2021-2032) Figure 45. China Biosimilar Revenue Share by Application (2021-2032) Figure 46. Asia Biosimilar Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Biosimilar Revenue Share by Type (2021-2032) Figure 48. Asia Biosimilar Revenue Share by Application (2021-2032) Figure 49. Asia Biosimilar Revenue Share by Region (2021-2032) Figure 50. Japan Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Biosimilar Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Biosimilar Revenue Share by Type (2021-2032) Figure 58. SAMEA Biosimilar Revenue Share by Application (2021-2032) Figure 59. SAMEA Biosimilar Revenue Share by Country (2021-2032) Figure 60. Brazil Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Biosimilar Monoclonal Antibodies
  • Biosimilar Insulin
  • Others
Applications
  • Cancer
  • Immunological Diseases
  • Diabetes
  • Others
Companies covered
  • Qilu Pharmaceutical
  • Bio-Thera
  • Zhejiang Hisun
  • Shanghai Henlius
  • Innovent Biologics
  • Jiangsu Hengrui
  • Gan&Lee
  • Tonghua Dongbao
  • United Laboratory
  • 3SBIO
  • Luye Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Biosimilar Market by Type
  3. 1.2.1 Global Biosimilar Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Biosimilar Monoclonal Antibodies
  5. 1.2.3 Biosimilar Insulin
  6. 1.2.4 Others
  7. 1.3 Biosimilar Market by Application
  8. 1.3.1 Global Biosimilar Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Cancer
  10. 1.3.3 Immunological Diseases
  11. 1.3.4 Diabetes
  12. 1.3.5 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Biosimilar Market Dynamics
  1. 2.1 Biosimilar Industry Trends
  2. 2.2 Biosimilar Industry Drivers
  3. 2.3 Biosimilar Industry Opportunities and Challenges
  4. 2.4 Biosimilar Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Biosimilar Market Perspective (2021-2032)
  2. 3.2 Global Biosimilar Growth Trends by Region
  3. 3.2.1 Global Biosimilar Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Biosimilar Market Size by Region (2021-2026)
  5. 3.2.3 Global Biosimilar Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Biosimilar Revenue by Players
  2. 4.1.1 Global Biosimilar Revenue by Players (2021-2026)
  3. 4.1.2 Global Biosimilar Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Biosimilar Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Biosimilar Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Biosimilar Key Players Headquarters & Area Served
  7. 4.4 Global Biosimilar Players, Product Type & Application
  8. 4.5 Global Biosimilar Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Biosimilar Market CR5 and HHI
  11. 4.6.3 2025 Biosimilar Tier 1, Tier 2, and Tier 3
5 Biosimilar Market Size by Type
  1. 5.1 Global Biosimilar Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Biosimilar Revenue by Type (2021-2032)
  3. 5.3 Global Biosimilar Revenue Market Share by Type (2021-2032)
6 Biosimilar Market Size by Application
  1. 6.1 Global Biosimilar Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Biosimilar Revenue by Application (2021-2032)
  3. 6.3 Global Biosimilar Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Qilu Pharmaceutical
  2. 7.1.1 Qilu Pharmaceutical Company Information
  3. 7.1.2 Qilu Pharmaceutical Business Overview
  4. 7.1.3 Qilu Pharmaceutical Biosimilar Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Qilu Pharmaceutical Biosimilar Product Portfolio
  6. 7.1.5 Qilu Pharmaceutical Recent Developments
  7. 7.2 Bio-Thera
  8. 7.2.1 Bio-Thera Company Information
  9. 7.2.2 Bio-Thera Business Overview
  10. 7.2.3 Bio-Thera Biosimilar Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Bio-Thera Biosimilar Product Portfolio
  12. 7.2.5 Bio-Thera Recent Developments
  13. 7.3 Zhejiang Hisun
  14. 7.3.1 Zhejiang Hisun Company Information
  15. 7.3.2 Zhejiang Hisun Business Overview
  16. 7.3.3 Zhejiang Hisun Biosimilar Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Zhejiang Hisun Biosimilar Product Portfolio
  18. 7.3.5 Zhejiang Hisun Recent Developments
  19. 7.4 Shanghai Henlius
  20. 7.4.1 Shanghai Henlius Company Information
  21. 7.4.2 Shanghai Henlius Business Overview
  22. 7.4.3 Shanghai Henlius Biosimilar Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Shanghai Henlius Biosimilar Product Portfolio
  24. 7.4.5 Shanghai Henlius Recent Developments
  25. 7.5 Innovent Biologics
  26. 7.5.1 Innovent Biologics Company Information
  27. 7.5.2 Innovent Biologics Business Overview
  28. 7.5.3 Innovent Biologics Biosimilar Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Innovent Biologics Biosimilar Product Portfolio
  30. 7.5.5 Innovent Biologics Recent Developments
  31. 7.6 Jiangsu Hengrui
  32. 7.6.1 Jiangsu Hengrui Company Information
  33. 7.6.2 Jiangsu Hengrui Business Overview
  34. 7.6.3 Jiangsu Hengrui Biosimilar Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Jiangsu Hengrui Biosimilar Product Portfolio
  36. 7.6.5 Jiangsu Hengrui Recent Developments
  37. 7.7 Gan&Lee
  38. 7.7.1 Gan&Lee Company Information
  39. 7.7.2 Gan&Lee Business Overview
  40. 7.7.3 Gan&Lee Biosimilar Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Gan&Lee Biosimilar Product Portfolio
  42. 7.7.5 Gan&Lee Recent Developments
  43. 7.8 Tonghua Dongbao
  44. 7.8.1 Tonghua Dongbao Company Information
  45. 7.8.2 Tonghua Dongbao Business Overview
  46. 7.8.3 Tonghua Dongbao Biosimilar Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Tonghua Dongbao Biosimilar Product Portfolio
  48. 7.8.5 Tonghua Dongbao Recent Developments
  49. 7.9 United Laboratory
  50. 7.9.1 United Laboratory Company Information
  51. 7.9.2 United Laboratory Business Overview
  52. 7.9.3 United Laboratory Biosimilar Revenue and Gross Margin (2021-2026)
  53. 7.9.4 United Laboratory Biosimilar Product Portfolio
  54. 7.9.5 United Laboratory Recent Developments
  55. 7.10 3SBIO
  56. 7.10.1 3SBIO Company Information
  57. 7.10.2 3SBIO Business Overview
  58. 7.10.3 3SBIO Biosimilar Revenue and Gross Margin (2021-2026)
  59. 7.10.4 3SBIO Biosimilar Product Portfolio
  60. 7.10.5 3SBIO Recent Developments
  61. 7.11 Luye Pharma
  62. 7.11.1 Luye Pharma Company Information
  63. 7.11.2 Luye Pharma Business Overview
  64. 7.11.3 Luye Pharma Biosimilar Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Luye Pharma Biosimilar Product Portfolio
  66. 7.11.5 Luye Pharma Recent Developments
8 North America
  1. 8.1 North America Biosimilar Revenue (2021-2032)
  2. 8.2 North America Biosimilar Revenue by Type (2021-2032)
  3. 8.2.1 North America Biosimilar Revenue by Type (2021-2026)
  4. 8.2.2 North America Biosimilar Revenue by Type (2027-2032)
  5. 8.3 North America Biosimilar Revenue Share by Type (2021-2032)
  6. 8.4 North America Biosimilar Revenue by Application (2021-2032)
  7. 8.4.1 North America Biosimilar Revenue by Application (2021-2026)
  8. 8.4.2 North America Biosimilar Revenue by Application (2027-2032)
  9. 8.5 North America Biosimilar Revenue Share by Application (2021-2032)
  10. 8.6 North America Biosimilar Revenue by Country
  11. 8.6.1 North America Biosimilar Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Biosimilar Revenue by Country (2021-2026)
  13. 8.6.3 North America Biosimilar Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Biosimilar Revenue (2021-2032)
  2. 9.2 Europe Biosimilar Revenue by Type (2021-2032)
  3. 9.2.1 Europe Biosimilar Revenue by Type (2021-2026)
  4. 9.2.2 Europe Biosimilar Revenue by Type (2027-2032)
  5. 9.3 Europe Biosimilar Revenue Share by Type (2021-2032)
  6. 9.4 Europe Biosimilar Revenue by Application (2021-2032)
  7. 9.4.1 Europe Biosimilar Revenue by Application (2021-2026)
  8. 9.4.2 Europe Biosimilar Revenue by Application (2027-2032)
  9. 9.5 Europe Biosimilar Revenue Share by Application (2021-2032)
  10. 9.6 Europe Biosimilar Revenue by Country
  11. 9.6.1 Europe Biosimilar Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Biosimilar Revenue by Country (2021-2026)
  13. 9.6.3 Europe Biosimilar Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Biosimilar Revenue (2021-2032)
  2. 10.2 China Biosimilar Revenue by Type (2021-2032)
  3. 10.2.1 China Biosimilar Revenue by Type (2021-2026)
  4. 10.2.2 China Biosimilar Revenue by Type (2027-2032)
  5. 10.3 China Biosimilar Revenue Share by Type (2021-2032)
  6. 10.4 China Biosimilar Revenue by Application (2021-2032)
  7. 10.4.1 China Biosimilar Revenue by Application (2021-2026)
  8. 10.4.2 China Biosimilar Revenue by Application (2027-2032)
  9. 10.5 China Biosimilar Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Biosimilar Revenue (2021-2032)
  2. 11.2 Asia Biosimilar Revenue by Type (2021-2032)
  3. 11.2.1 Asia Biosimilar Revenue by Type (2021-2026)
  4. 11.2.2 Asia Biosimilar Revenue by Type (2027-2032)
  5. 11.3 Asia Biosimilar Revenue Share by Type (2021-2032)
  6. 11.4 Asia Biosimilar Revenue by Application (2021-2032)
  7. 11.4.1 Asia Biosimilar Revenue by Application (2021-2026)
  8. 11.4.2 Asia Biosimilar Revenue by Application (2027-2032)
  9. 11.5 Asia Biosimilar Revenue Share by Application (2021-2032)
  10. 11.6 Asia Biosimilar Revenue by Country
  11. 11.6.1 Asia Biosimilar Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Biosimilar Revenue by Country (2021-2026)
  13. 11.6.3 Asia Biosimilar Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Biosimilar Revenue (2021-2032)
  2. 12.2 SAMEA Biosimilar Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Biosimilar Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Biosimilar Revenue by Type (2027-2032)
  5. 12.3 SAMEA Biosimilar Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Biosimilar Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Biosimilar Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Biosimilar Revenue by Application (2027-2032)
  9. 12.5 SAMEA Biosimilar Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Biosimilar Revenue by Country
  11. 12.6.1 SAMEA Biosimilar Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Biosimilar Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Biosimilar Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst